Related references
Note: Only part of the references are listed.Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer
Tanya B. Dorff et al.
CLINICAL CANCER RESEARCH (2022)
177Lu-PSMA-617 versus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial
Swayamjeet Satapathy et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
GD2-CART cell therapy for H3K27M-mutated diffuse midline gliomas
Robbie G. Majzner et al.
NATURE (2022)
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
Thomas Powles et al.
NATURE MEDICINE (2022)
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer The VIABLE Phase 3 Randomized Clinical Trial
Nicholas J. Vogelzang et al.
JAMA ONCOLOGY (2022)
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up
James A. Eastham et al.
JOURNAL OF UROLOGY (2022)
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions
James A. Eastham et al.
JOURNAL OF UROLOGY (2022)
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design
Karim Fizazi et al.
LANCET (2022)
Androgen receptor activity in T cells limits checkpoint blockade efficacy
Xiangnan Guan et al.
NATURE (2022)
CAR T cells reach clinical milestone in prostate cancer
Nicholas P. Tschernia et al.
NATURE MEDICINE (2022)
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
Vivek Narayan et al.
NATURE MEDICINE (2022)
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
Douglas G. McNeel et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
Ryon P. Graf et al.
JAMA NETWORK OPEN (2022)
Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs
Xiaokang Zhang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer
Yishen Wang et al.
NATURE REVIEWS UROLOGY (2022)
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Karim Fizazi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Cabozantinib combination therapy for the treatment of solid tumors: a systematic review
Daniel Castellano et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Michael J. Giffin et al.
CLINICAL CANCER RESEARCH (2021)
Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer
Catherine H. Marshall et al.
CLINICAL CANCER RESEARCH (2021)
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer
May Daher et al.
CANCER DISCOVERY (2021)
Exosome-based liquid biopsies in cancer: opportunities and challenges
W. Yu et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
Petra Deegen et al.
CLINICAL CANCER RESEARCH (2021)
BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers
Nikhil V. Kamat et al.
CLINICAL CANCER RESEARCH (2021)
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Daniel P. Petrylak et al.
CLINICAL CANCER RESEARCH (2021)
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2021)
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
Horst-Dieter Hummel et al.
IMMUNOTHERAPY (2021)
Prostate Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines
Edward Schaeffer et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman et al.
LANCET (2021)
FDA approves fourth CAR-T cell therapy
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Elise A. Chong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
Ravi A. Madan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
Jonas S. Heitmann et al.
CANCERS (2021)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
Cross-resistance and drug sequence in prostate cancer
Stefan A. J. Buck et al.
DRUG RESISTANCE UPDATES (2021)
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Ignacio Melero et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Industrializing engineered autologous T cells as medicines for solid tumours
Cedrik M. Britten et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Navigating CAR-T cells through the solid-tumour microenvironment
Andrew J. Hou et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
Meenal Sinha et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Next Generation Sequencing Technology in the Clinic and Its Challenges
Lau K. Vestergaard et al.
CANCERS (2021)
A Phase lb Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Lawrence Fong et al.
CLINICAL CANCER RESEARCH (2021)
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer
Daniel P. Petrylak et al.
FUTURE ONCOLOGY (2021)
Prostate cancer
Shahneen Sandhu et al.
LANCET (2021)
The potential of CAR T cell therapy for prostate cancer
Philipp Wolf et al.
NATURE REVIEWS UROLOGY (2021)
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer
Kai Shen et al.
FRONTIERS IN ONCOLOGY (2021)
Interleukins in cancer: from biology to therapy
Dania Briukhovetska et al.
NATURE REVIEWS CANCER (2021)
Metabolic barriers to cancer immunotherapy
Kristin DePeaux et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Systemic immunity in cancer
Kamir J. Hiam-Galvez et al.
NATURE REVIEWS CANCER (2021)
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Revisiting Immunotherapy: A Focus on Prostate Cancer
Ha-Ram Cha et al.
CANCER RESEARCH (2020)
The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types
Hermann Einsele et al.
CANCER (2020)
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
Sumit K. Subudhi et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
Houssein Abdul Sater et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold
Kento Fujiwara et al.
CELLS (2020)
T cell-engaging therapies - BiTEs and beyond
Maria-Elisabeth Goebeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Christos E. Kyriakopoulos et al.
CLINICAL CANCER RESEARCH (2020)
Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy
Mayassa J. Bou-Dargham et al.
BMC CANCER (2020)
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes
Claps Melanie et al.
CANCER TREATMENT REVIEWS (2020)
Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer
Isabel Ben-Batalla et al.
FRONTIERS IN IMMUNOLOGY (2020)
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
Padmanee Sharma et al.
CANCER CELL (2020)
Precision Oncology for Metastatic Prostate Cancer: Translation into Practice
Maria De Santis et al.
EUROPEAN UROLOGY (2020)
Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion
Bianca Cioni et al.
NATURE COMMUNICATIONS (2020)
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Eric Powers et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Advanced Prostate Cancer: Treatment Advances and Future Directions
Umang Swami et al.
TRENDS IN CANCER (2020)
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L. Gulley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer
Celestia S. Higano et al.
CANCER (2019)
Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy
Shiping Jiao et al.
CELL (2019)
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
K. M. Heinhuis et al.
ANNALS OF ONCOLOGY (2019)
CAR-T cell therapy: a potential new strategy against prostate cancer
Giuseppe Schepisi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen et al.
CANCER RESEARCH (2019)
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer
Douglas G. McNeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A. R. Hansen et al.
ANNALS OF ONCOLOGY (2018)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers
Daniel J. McGrail et al.
NATURE COMMUNICATIONS (2018)
CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment
Clare Y. Slaney et al.
CANCER DISCOVERY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
Ellen Wargowski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
Angela Rita Elia et al.
FRONTIERS IN IMMUNOLOGY (2018)
Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross A. Stewart et al.
CANCER RESEARCH (2018)
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories
Kyle J. Foreman et al.
LANCET (2018)
Targeted Alpha Therapy, an Emerging Class of Cancer Agents A Review
Christopher Parker et al.
JAMA ONCOLOGY (2018)
Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis
Marie Christine Hupe et al.
FRONTIERS IN ONCOLOGY (2018)
Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer
Jitka Fucikova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Friederike Braig et al.
BLOOD (2017)
Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao et al.
NATURE MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
Akash Patnaik et al.
CANCER DISCOVERY (2017)
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Elizabeth H. Stover et al.
CLINICAL CANCER RESEARCH (2016)
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
Matthew Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Fred Saad et al.
LANCET ONCOLOGY (2016)
Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse
Yang Pu et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
Michael T. Schweizer et al.
ONCOTARGET (2016)
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Julie N. Graff et al.
ONCOTARGET (2016)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
Michal Podrazil et al.
ONCOTARGET (2015)
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
Douglas G. McNeel et al.
CLINICAL CANCER RESEARCH (2014)
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
Peter Hoskin et al.
LANCET ONCOLOGY (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin et al.
ANNALS OF ONCOLOGY (2013)
Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
David C. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
FDA Approves Radiopharmaceutical for Metastatic Prostate Cancer
Cancer Discovery (2013)
A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells
Kosuke Yamamoto et al.
BIOCHEMICAL JOURNAL (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
Wilfred D. Stein et al.
CLINICAL CANCER RESEARCH (2011)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sipuleucel-T
Celestia S. Higano et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy
Ravi A. Madan et al.
CLINICAL CANCER RESEARCH (2008)
Neonatal castration affects intrathymic kinetics of T-cell differentiation and the spleen T-cell level
K. Radojevic et al.
JOURNAL OF ENDOCRINOLOGY (2007)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer
Z Gu et al.
ONCOGENE (2000)